Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis

Clinical and Experimental Allergy

Volumn 42, Issue 2, 2012, Pages 248-254

  Tang, Y H ^a,f   Mockenhaupt, M ^b,e   Henry, A ^a,g   Bounoua, M ^c,e   Naldi, L ^d,e   Le Gouvello, S ^a,e   Bensussan, A ^a,h   Roujeau, J C ^a,e  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b UNIVERSITY OF FREIBURG   (Germany)

^c HENRI MONDOR HOSPITAL   (France)

^d OSPEDALI RIUNITI   (Italy)

^e RegiSCAR Study Group (Multinational)   (Italy)

^f UNIVERSITY OF ULSTER   (United Kingdom)

^g INSERM U955   (France)

^h SAINT LOUIS HOSPITAL   (France)

Author keywords

Adverse drug reaction; Lamotrigine; Lymphocyte proliferation assay; Regulatory T cells; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; LAMOTRIGINE; PHYTOHEMAGGLUTININ; THYMIDINE;

ANTICONVULSANT THERAPY; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ERUPTION; DRUG EXPOSURE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LYMPHOCYTE TRANSFORMATION TEST; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STEVENS JOHNSON SYNDROME; T CELL DEPLETION; TOXIC EPIDERMAL NECROLYSIS;

ANTICONVULSANTS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; MALE; MITOGENS; PHYTOHEMAGGLUTININS; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME; T-LYMPHOCYTES, REGULATORY; TRIAZINES;

EID: 84856438378     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03875.x     Document Type: Article

References (20)

1. Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128:35-44.
2. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy 2007; 37:989-99.
3. Waton J, Tréchot P, Loss-Ayav C, Schmutz JL, Barbaud A. Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions. Br J Dermatol 2009; 160:786-94.
4. Sanz ML, Gamboa PM, García-Avilés C, De Weck A. Drug hypersensitivities: which room for biological tests? Eur Ann Allergy Clin Immunol 2005; 37:230-5.
5. Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug Saf 2009; 32:391-408.
6. Sachs B, Rönnau AC, von Schmiedeberg S, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997; 195:60-4.
7. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE et al. Characterization of drug-specific T-cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111:1393-403.
8. Nassif A, Bensussan A, Boumsell L et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T-cells. J Allergy Clin Immunol 2004; 114:1209-15.
9. Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14:1343-50.
10. de AE, Dessirier V, Laprée G et al. Death ligand TRAIL, secreted by CD1a+ and CD14 + cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol 2011; 20:107-12.
11. Wolkenstein P, Chosidow O, Fléchet ML et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35:234-6.
12. Roujeau JC, Albengres E, Moritz S et al. Lymphocyte transformation test in drug-induced toxic epidermal necrolysis. Int Arch Allergy Appl Immunol 1985; 78:22-4.
13. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug hypersensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62:1439-44.
14. Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T-cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009; 182:8071-9.
15. Azukizawa H. Animal models of toxic epidermal necrolysis. J Dermatol 2011; 38:255-60.
16. Sekula P, Liss Y, Davidovici B et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 2011; 32:237-45.
17. Sassolas B, Haddad C, Mockenhaupt M et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88:60-8.
18. Roujeau JC, Moritz S, Guillaume JC et al. Lymphopenia and abnormal balance of T-lymphocyte subpopulations in toxic epidermal necrolysis. Arch Dermatol Res 1985; 277:24-7.
19. Porebski G, Gschwend-Zawodniak A, Pichler WJ. In-vitro diagnosis of T cell-mediated drug allergy. Clin Exp Allergy 2011; 41:461-70.
20. Kauppinen K. Cutaneous reactions to drugs with special reference to severe bullous mucocutaneous eruptions and sulphonamides. Acta Derm Venereol 1972; 68:s1-89.